Long-term hematopoiesis in transplantation survivors

This is an observational, explorative study, embedded in the HSCT LATER outpatient clinic of the Princess Máxima Center. The study visit will be combined with a clinical visit, as part of regular post-HSCT follow-up. All participants will undergo clinical assessment of HSCT-related long-term effects by a trained physician, including measurement of differential blood counts, as part of routine clinical care. For this study, we will use these clinical data, and collect an additional blood sample for in-depth assessment of hematopoietic integrity after HSCT.

Hematopoietic stem cell transplantation (HSCT) is a last-resort, curative therapy for patients suffering from various, otherwise lethal, diseases. Due to improved treatment strategies, the number of HSCT survivors and their life expectancy continue to increase1. In pediatric HSCT survivors, the donor stem cells may have to live far beyond the normal human life span2. It remains unknown whether transplanted HSCs can sustain life-long healthy blood production in these recipients. In the current project, we hypothesize that HSCT compromises HSC longevity and predisposes to (age-related) hematopoietic dysfunction in the recipient.

Single collection of peripheral blood >5 years after HSCT

From each HSCT survivor, we will collect up to 50 mL peripheral blood. For participants <25 kg, the volume of blood will be adjusted to 2 mL per kg bodyweight (2.5% of total blood volume).